Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-Current Assets (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Non-Current Assets for 16 consecutive years, with $687.3 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 9.09% to $687.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 billion through Dec 2025, up 27.96% year-over-year, with the annual reading at $687.3 million for FY2025, 9.09% down from the prior year.
  • Non-Current Assets hit $687.3 million in Q4 2025 for Ani Pharmaceuticals, down from $709.8 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $766.1 million in Q3 2024 to a low of $279.1 million in Q3 2021.
  • Historically, Non-Current Assets has averaged $487.4 million across 5 years, with a median of $422.4 million in 2022.
  • Biggest five-year swings in Non-Current Assets: dropped 13.14% in 2021 and later soared 102.68% in 2025.
  • Year by year, Non-Current Assets stood at $449.8 million in 2021, then dropped by 7.56% to $415.8 million in 2022, then fell by 7.51% to $384.6 million in 2023, then surged by 96.57% to $756.0 million in 2024, then dropped by 9.09% to $687.3 million in 2025.
  • Business Quant data shows Non-Current Assets for ANIP at $687.3 million in Q4 2025, $709.8 million in Q3 2025, and $740.4 million in Q2 2025.